Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- GSK Japan’s Fauchet Bows Out as Chairman
February 14, 2019
- Avanir, DOJ Reach Agreement over Nuedexta Marketing Activity Case
February 14, 2019
- Eisai Files Fycompa in Europe for Pediatric Use
February 14, 2019
- MSD Files Keytruda/Inlyta Combo in Japan as 1st-Line Therapy for RCC
February 14, 2019
- Generic Player Ohara Looks to Morph into Innovative Drug Maker, with Focus on Oncology
February 13, 2019
- Takeda’s Adcetris Gets European OK for 1st-Line Stage IV Hodgkin’s Lymphoma
February 13, 2019
- Astellas/Pfizer Unveil Positive Xtandi Data for Hormone-Sensitive Prostate Cancer
February 13, 2019
- Oncolys in Talks with Checkpoint Drug Makers for Telomelysin: President
February 12, 2019
- US Latuda Sales Might Fall Short as Lawsuits Weigh: Sumitomo Dainippon Chief
February 12, 2019
- Xofluza Top Seller in Japan in January: Encise Snapshot
February 12, 2019
- Mochida Seeks Label Expansion for Dinagest in Japan
February 12, 2019
- Pfizer Initiates Voluntary Recall of Exforge Generics after Discovery of Carcinogenic Substances Above Limits
February 12, 2019
- Sumitomo Dainippon, Aikomi Join Forces for Research on Medical Devices to Relieve BPSD
February 12, 2019
- Ethical Drug Sales Down 4.5% in December: Crecon
February 8, 2019
- SymBio Targets 11.8 Billion Yen Sales in 2022 under New 4-Year Biz Plan
February 8, 2019
- Torii Aims to Turn Profit in 2022, Forecasting Revenue Drop after Gilead HIV Pact Ends
February 8, 2019
- Torii to Sell Futhan to Nichi-Iko after 43% Off-Patent Price Slash
February 7, 2019
- Goichi Matsuda Named as New President of Torii
February 7, 2019
- Torii Launches Early Retirement Program as Part of Restructuring Plan
February 7, 2019
- Daiichi Sankyo’s Cancer Med Pexidartinib Gets Priority Review in US
February 7, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…